前列腺癌患者去势后雄激素前体水平的广泛改变及其与活性雄激素水平的关联
研究分析了99例前列腺癌患者的116份血清样本,按性腺功能正常、去势敏感、去势抵抗及去势抵抗接受阿比特龙治疗分组,用质谱法检测15种类固醇水平。去势治疗显著降低13种类固醇水平,去势后雄烯二酮与睾酮相关,双氢睾酮与睾酮及后门通路代谢物雄酮相关,提示去势抵抗患者存在肿瘤相关循环雄激素。
要点
- 去势敏感前列腺癌患者较性腺功能正常者多种类固醇水平显著降低。
- 去势后双氢睾酮水平与睾酮及后门通路代谢物雄酮相关。
- 去势抵抗患者中雄烯二酮与睾酮显著相关,提示肿瘤相关循环雄激素。
核心结论
- 雄激素剥夺治疗显著降低13种循环类固醇水平。
- 去势后后门通路代谢物雄酮与双氢睾酮水平强相关,去势抵抗条件下雄烯二酮与睾酮显著相关,提示肿瘤相关循环雄激素存在。
研究设计与样本
- 共收集99例前列腺癌患者的116份血清样本,分为性腺功能正常、去势敏感前列腺癌、去势抵抗前列腺癌及去势抵抗接受醋酸阿比特龙治疗四组。
- 用质谱法检测15种类固醇血清水平,组间比较采用方差分析,个体内关联采用Pearson相关和线性回归分析。
主要发现
- 去势敏感前列腺癌(去势)患者较性腺功能正常者,睾酮、双氢睾酮、雄烯二酮、脱氢表雄酮、脱氢表雄酮硫酸盐、雄酮、雄烯二醇、雌酮、雌酮硫酸盐、雌二醇及雄酮/3α-二醇-3/3α-二醇-17-葡萄糖醛酸苷水平显著降低。
- 性腺功能正常条件下睾酮水平与多种类固醇强相关,而去势患者中睾酮受前体类固醇影响较弱。
- 雄激素剥夺治疗下双氢睾酮水平与睾酮及后门通路代谢物雄酮相关。
- 去势抵抗前列腺癌患者中雄烯二酮水平与睾酮水平显著相关,睾酮是唯一与双氢睾酮水平相关的类固醇。
临床怎么用
- 作者认为这些结果为在前列腺癌患者中强化雄激素受体轴信号通路抑制剂治疗提供了进一步依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dihydrotestosterone and testosterone are thought to be major contributors of prostate cancer progression and resistance. We studied the modulation of 15 circulating steroids by castration and their association with dihydrotestosterone and testosterone levels. MATERIALS METHODS: A total of 116 serum samples were collected from 99 prostate cancer patients and categorized as eugonadal, castration-sensitive prostate cancer, castration-resistant prostate cancer, or castration-resistant prostate cancer under abiraterone acetate. Serum levels of 15 steroids were measured using mass spectrometry and compared between groups using analysis of variance. Intrapatient association of steroid levels and the androgens testosterone and dihydrotestosterone were assessed using Pearson correlation and linear regression. RESULTS: Testosterone, dihydrotestosterone, androstenedione, dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androsterone, androstenediol, estrone, estrone-sulfate, estradiol, and androsterone/3α-diol-3/3α-diol-17-glucuronide levels were significantly decreased in castration-sensitive prostate cancer (castrated) compared to eugonadal patients. Testosterone levels were strongly associated with multiple steroids under eugonadal conditions, whereas they were weakly affected by precursor steroids in castrated patients. By contrast, dihydrotestosterone levels under androgen deprivation therapy were associated with testosterone and the backdoor pathway metabolite androsterone. In castration-resistant prostate cancer patients, levels of androstenedione were significantly associated with testosterone level, while testosterone was the only steroid associated with dihydrotestosterone levels. CONCLUSIONS: Androgen deprivation therapy significantly reduces the levels of 13 circulating steroids. Upon androgen deprivation therapy initiation, the backdoor pathway metabolite androsterone are strongly associated with dihydrotestosterone levels. Under castration-resistant prostate cancer conditions, androstenedione was significantly associated with testosterone levels, suggesting the presence of tumor-related circulating androgens in these patients. These results provide further rationale to intensify treatments with androgen receptor axis signaling pathway inhibitors in patients with prostate cancer.
引用
- Rouleau M, Neveu B, Caron P, et al. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level. J Urol. 2022. PMID: 36102111. doi:10.1097/JU.0000000000002923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。